Difference between revisions of "Part:BBa K404314"
Line 79: | Line 79: | ||
<h4 style="margin-left: 0cm; text-indent: 0cm;">Infectious Titer by | <h4 style="margin-left: 0cm; text-indent: 0cm;">Infectious Titer by | ||
qPCR </h4> | qPCR </h4> | ||
− | <p class="MsoNormal"><span style="font-size: 10pt; line-height: 150%;" | + | <p class="MsoNormal"><span style="font-size: 10pt; line-height: 150%; text-decoration: justify;" |
lang="EN-US"> | lang="EN-US"> | ||
We transfected 250.000 AAV-293 cells with 1 µg of total DNA composed of | We transfected 250.000 AAV-293 cells with 1 µg of total DNA composed of |
Revision as of 17:21, 29 October 2010
DARPin-E01
[DARPin-E01 | |
---|---|
BioBrick Nr. | BBa_K404314 |
RFC standard | RFC 25 |
Requirement | pSB1C3 |
Source | |
Submitted by | [http://2010.igem.org/Team:Freiburg_Bioware FreiGEM 2010] |
Natural protein ankyrin repeat (AR) molecules are motifs that can be found commonly in proteins (Bork 1993). These motifs mediate protein-protein interactions suggesting that AR proteins can be used for designing new binding molecules. Design of structural scaffolds with consensus regions and randomized positions of interacting residues leads to improved biophysical characteristics of targeting molecules (Binz et al. 2003) (Kohl et al. 2003).
The repetitive nature of the ankyrin proteins allows modifications in their variable and modular binding surface. Therefore, consensus sequences of natural ankyrin proteins have been used to design novel and stable scaffolds for binding proteins.
Characterization
Specific targeting of tumor cells was, besides producing recombinant virus particles for therapeutical applications, one intention of the Virus Construction Kit provided by the iGEM team Freiburg_Bioware 2010.
For development of targeting strategies against EGF receptor (EGFR) over-expressing cancer cells, exhaustive literature search for engineering the surface of the Adeno-associated virus 2 (AAV2) was performed.
Besides insertion of targeting motifs into the viral protein 1 (VP1) open reading frame (ORF), we designed a method for fusing larger motifs to the N-terminus of VP2. It is expected that these peptides become located on the virus surface either by transit through the pores or by exposure during capsid assembly.
Additionally it is required to knock down the natural
tropism of the
virus towards its primary receptor heparan sulfate proteoglycan (HSPG)
in order
to prevent infection of healthy cells (Perabo et al. 2006). The binding
motif
consists of five amino-acids located on the capsid surface: R484/R487,
K532,
R585/587. (Trepel et al. 2009). The positively charged arginine
residues
interact with the HSPGs' negatively charged acid residues. Two point
mutations
(R585A and R588A) are sufficient to eliminate the heparin binding
affinity of AAV2 (Opie et al. 2003)
We transfected 250.000 AAV-293 cells with 1 µg of total DNA composed of
equal amounts of Rep/Cap, pHelper and vector plasmid. VP2 fusion plasmids
were co-transfected with two different ratios in respect to Rep/Cap(VP2KO).
The resulting AAV2 particles were produced in two versions: With or without HSPG
binding affinity knock down (587KO). Viruses
were harvested three days post transfection. The genomic titer was
determined
via qPCR by amplification of a specific sequence located in the CMV
promoter of
the vector plasmid (Table 1). Table 1: Quantitative Real-Time
PCR.
Determination of genomic titer. Data were
corrected for negative control value. Co-transfected
Construct Ratio Genomic
Titer /1ml Corrected
For Negative Control DARPin_MiddleLinker_VP2/3 25:75 4,36E+08 DARPin_MiddleLinker_VP2/3 50:50 3,93E+08 DARPin_MiddleLinker_VP2/3(587KO) 25:75 1,00E+09 DARPin_MiddleLinker_VP2/3(587KO) 50:50 3,99E+08 Control: Rep/Cap 100% 1,55E+08 Control: Rep/Cap(587KO) 100% 5,39E+08 We
investigated transduction of
different cell lines. For this purpose 100.000 HT1080, HeLa or A431
cells were
seeded and transduced with 50 µL virus stock and harvested 24 hours
later.
Infectious titers were determined via qPCR and normalized to the
genomic titers. Figure 1
shows infection efficacy of
DARPin exposing viruses. Transduction of HT1080 cells was almost not
affected
as long as binding to HSPG was not knocked down. HeLa cells were also
infected
less efficient compared to the controls. However, A431 cells which over
express
EGFR were not infected by the controls. Transduction is rescued by
integration
of the DARPin into the virus capsid. By additionally knocking down the
HSPG
binding affinity these cells are transduced 10 times better, reaching
wild type
capsid HT1080 infection efficacy. These results indicated that specific
re-targeting of AAV2 virus particles towards EGFR over expressing tumor
cells
was achieved by N-terminal fusion of targeting motifs to VP2. Figure 1: DARPin E01 VP2 Fusion. Infectious
titers were determined with or without HSPG knock down for HT1080, HeLa
and
A431 cells. Control:Rep/Cap plasmid with and without HSPG knock down.
Infectious Titer by
qPCR